Liminal BioSciences
Liminal BioSciences, previously known as Prometic, is a biopharmaceutical company developing small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Buyout | |
| Total Funding | 000k | ||
| CAD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 10 % | (81 %) | (32 %) | (81 %) | (38 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (555 %) | (951 %) | (4093 %) | (2587 %) | (7032 %) | (7944 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (492 %) | (793 %) | (4195 %) | (3555 %) | 2003 % | 125 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 419 % | 344 % | 1532 % | 1713 % | 2853 % | 3815 % |
Source: Company filings or news article
Related Content
Liminal BioSciences is a biopharmaceutical company focused on developing innovative therapies for patients with rare and unmet medical needs, particularly in the fields of fibrosis and orphan diseases. The company operates in the biopharmaceutical market, targeting conditions that have limited treatment options. Liminal BioSciences serves a niche clientele, including patients suffering from idiopathic pulmonary fibrosis and plasminogen deficiency, among other rare conditions. The business model revolves around research and development (R&D) of small molecule therapeutics, leveraging their expertise to create a robust pipeline of potential best-in-class drugs. Revenue is generated through the development and commercialization of these therapies, often in collaboration with larger pharmaceutical companies or through direct sales upon regulatory approval. The company is committed to advancing its R&D pipeline, which includes selective GPR84 and OXER1 antagonists, to bring new treatments to market.
Keywords: fibrosis, orphan diseases, biopharmaceutical, small molecules, R&D, idiopathic pulmonary fibrosis, plasminogen deficiency, GPR84 antagonist, OXER1 antagonist, innovative therapies.